Larimar Therapeutics
(NASDAQ) LRMR
Larimar Therapeutics Financials at a Glance
Market Cap
$498.80M
Revenue (TTM)
$0.00
Net Income (TTM)
$165.67M
EPS (TTM)
$-2.21
P/E Ratio
-2.17
Dividend
$0.00
Beta (Volatility)
1.14 (Average)
Dividend
$0.00
Beta (Volatility)
1.14 (Average)
Price
$4.78
Volume
994,381.097
Open
$4.57
Price
$4.78
Volume
994,381.097
Open
$4.57
Previous Close
$4.79
Daily Range
$4.51 - $4.80
52-Week Range
$1.61 - $6.42
Dividend
$0.00
Beta (Volatility)
1.14 (Average)
Price
$4.78
Volume
994,381.097
Open
$4.57
Previous Close
$4.79
Daily Range
$4.51 - $4.80
52-Week Range
$1.61 - $6.42
LRMR News
LRMR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Larimar Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
71
CEO
Carole S. Ben-Maimon, MD
Website
larimartx.comHeadquarters
Bala Cynwyd, PA 19004, US
LRMR Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-133%
Return on Capital
-2%
Return on Assets
-1%
Earnings Yield
-46.08%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$498.80M
Shares Outstanding
104.13M
Volume
994.38K
Short Interest
0.00%
Avg. Volume
4.19M
Financials (TTM)
Gross Profit
$350.00K
Operating Income
$172.50M
EBITDA
$172.50M
Operating Cash Flow
$113.20M
Capital Expenditure
$91.00K
Free Cash Flow
$113.29M
Cash & ST Invst.
$136.85M
Total Debt
$4.07M
Larimar Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$87.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$498.80M
N/A
Market Cap/Employee
$7.67M
N/A
Employees
65
N/A
Net Income
$62.50M
-116.8%
EBITDA
$63.93M
-104.8%
Quarterly Fundamentals
Net Cash
$132.78M
-25.5%
Accounts Receivable
$747.00K
-29.1%
Inventory
$0.00
N/A
Long Term Debt
$2.96M
-27.0%
Short Term Debt
$1.10M
+4.2%
Return on Assets
-1.14%
N/A
Return on Invested Capital
-2.13%
N/A
Free Cash Flow
$38.53M
-75.2%
Operating Cash Flow
$38.53M
-76.6%